University of Naples Federico II at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

University of Naples Federico II takes part in 3 sessions at ESMO 2026 in Madrid. Its program centres on liquid biopsy, from multi-cancer early detection tests to circulating tumour DNA as a guide for treating early-stage non-small cell lung cancer. It also presents final results of the GIM3 FATA trial comparing aromatase inhibitors and schedules in postmenopausal women with hormone receptor-positive early breast cancer.

Organization

ESMO 2026 Attendance

University of Naples Federico II

Naples, Italy

unina.it

University & institute

Public university in Naples, Italy, with a school of medicine and surgery and a university hospital.

Satellite

Fri Oct 23
09:45–11:15

Gene Solutions - AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation

with The Chinese University of Hong Kong

Biomarkers & precision oncology

Satellite

Fri Oct 23
09:51–10:03

Clinical Challenges with Multi-Cancer Early Detection Tests: Unmet Needs and Lessons for Next-Generation Approaches in Precision Oncology

Gene Solutions - AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation

Biomarkers & precision oncology

Satellite

Fri Oct 23
11:12–11:32

Closing

Gene Solutions - AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation

Biomarkers & precision oncology

Abstract

Fri Oct 23
16:15–16:20

544RO - Final analysis of the GIM3 FATA trial: treatment schedule and three aromatase inhibitors (AIs) comparison in postmenopausal HR-positive (HR+) early breast cancer (eBC)

Rapid oral: Breast cancer, early stage

Breast cancer

Chair

Sun Oct 25
14:45–15:30

Is it time to use ctDNA to guide treatment in early stage NSCLC?

Lung & thoracic cancers